MicroRNAs in cancer: Biomarkers, functions and therapy

Trends in Molecular Medicine

Volumn 20, Issue 8, 2014, Pages 460-469

  Hayes, Josie ^a   Peruzzi, Pier Paolo ^b   Lawler, Sean ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Clinical; MicroRNA; Prognosis; Signature

Indexed keywords

MICRORNA; TUMOR MARKER;

ANIMAL; BLOOD; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE THERAPY; GENETICS; HUMAN; NEOPLASMS; PROCEDURES; PROGNOSIS;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC THERAPY; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905122848     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.06.005     Document Type: Review

References (79)

1. Ebert M.S., Sharp P.A. Roles for microRNAs in conferring robustness to biological processes. Cell 2012, 149:515-524.
2. Choudhury Y., et al. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. J. Clin. Invest. 2012, 122:4059-4076.
3. Stahlhut C., Slack F.J. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013, 5:111.
4. Lu J., et al. MicroRNA expression profiles classify human cancers. Nat Cell Biol 2005, 435:834-838.
5. Dvinge H., et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497:378-382.
6. Kim T-M., et al. A developmental taxonomy of glioblastoma defined and maintained by microRNAs. Cancer Res. 2011, 71:3387-3399.
7. Manterola L., et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014, 16:520-527.
8. Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 2013, 31:577.
9. Lee R.C., et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
10. Griffiths-Jones S., et al. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-D158.
11. Krol J., et al. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
12. Calin G.A., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
13. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
14. Chiocca E.A., Lawler S.E. The many functions of microRNAs in glioblastoma. World Neurosurg. 2010, 73:598-601.
15. Godlewski J., et al. microRNA-451: a conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010, 9:2742-2748.
16. Ziebarth J.D., et al. Integrative analysis of somatic mutations altering microRNA targeting in cancer genomes. PLoS ONE 2012, 7:e47137.
17. Sun G., et al. SNPs in human miRNA genes affect biogenesis and function. RNA 2009, 15:1640-1651.
18. Melo S.A., et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010, 18:303-315.
19. Kuang Y., et al. Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol. Lett. 2013, 5:1149-1154.
20. Gu S., et al. The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell 2012, 151:900-911.
21. Wan G., et al. DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Rep. 2013, 3:2100-2112.
22. Auyeung V.C., et al. Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. Cell 2013, 152:844-858.
23. Xhemalce B., et al. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell 2012, 151:278-288.
24. Choudhury Y., et al. Attenuated adenosine-to-inosine editing of microRNA-376a promotes invasiveness of glioblastoma cells. J. Clin. Invest. 2012, 122:4059-4076.
25. Ota H., et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013, 153:575-589.
26. Ebert M.S., et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4:721-726.
27. Tay Y., et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.
28. Memczak S., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2014, 495:333-338.
29. Hansen T.B., et al. Circular RNA and miR-7 in Cancer. Cancer Res. 2013, 73:5609-5612.
30. Kumar M.S., et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature 2014, 505:212-217.
31. Sumazin P., et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011, 147:370-381.
32. Chi S.W., et al. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009, 460:479-486.
33. Boudreau R.L., et al. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron 2014, 81:294-305.
34. Hu C-W., et al. Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. J. Proteome Res. 2013, 12:3993-4004.
35. Sandhu S.K., et al. B-cell malignancies in microRNA Emu-miR-17~92 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18208-18213.
36. Mavrakis K.J., et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat. Genet. 2011, 43:673-678.
37. Lerner R.G., Petritsch C. A microRNA-operated switch of asymmetric-to-symmetric cancer stem cell divisions. Nat. Cell Biol. 2014, 16:212-214.
38. Hwang W-L., et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat. Cell Biol. 2014, 16:268-280.
39. Hao J., et al. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int. J. Cancer 2014, 135:1019-1027.
40. Kim N.H., et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 2011, 195:417-433.
41. Song S.J., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
42. Liu X., et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J. 2011, 440:23-31.
43. Kong W., et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28:6773-6784.
44. Shen J., et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2014, 497:383-387.
45. Wang Y., et al. p53 is positively regulated by miR-542-3p. Cancer Res. 2014, 74:3218-3227.
46. Farazi T.A., et al. Bioinformatic analysis of barcoded cDNA libraries for small RNA profiling by next-generation sequencing. Methods 2012, 58:171-187.
47. Nair V.S., et al. Clinical outcome prediction by microRNAs in human cancer: a systematic review. JNCI J. Natl. Cancer Inst. 2012, 104:528-540.
48. Pan X., et al. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 2010, 10:1224-1232.
49. Rosenfeld N., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26:462-469.
50. Wandt H., et al. WHO classification of myeloid neoplasms and leukemia. Blood 2010, 115:748-749. author reply 749-750.
51. Garzon R., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
52. Liu C., et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012, 72:3393-3404.
53. Farazi T.A., et al. Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol. 2014, 15:R9.
54. Andorfer C.A., et al. MicroRNA signatures: clinicalbiomarkers for the diagnosis andtreatment of breast cancer. Trends Mol. Med. 2011, 17:313-319.
55. Pencheva N., Tavazoie S.F. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 2013, 15:546-554.
56. Png K.J., et al. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012, 481:190-194.
57. Díaz-Martín J., et al. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 2014, 232:319-329.
58. Scholl V., et al. Leukemia research. Leukemia Res. 2012, 36:119-121.
59. Sebio A., et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet. Genomics 2013, 23:142-147.
60. Pardini B., et al. Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: a potential modulation of microRNAs binding. Clin. Cancer Res. 2013, 19:6044-6056.
61. Wynendaele J., et al. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010, 70:9641-9649.
62. Ding C., et al. A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer. Onco Targets Ther. 2013, 6:877-881.
63. Wu Y., et al. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS ONE 2011, 6:e29043.
64. Chin L.J., et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68:8535-8540.
65. Schwarzenbach H., et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 2014, 11:145-156.
66. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
67. Wang Y., et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013, 73:4801-4809.
68. Jarry J., et al. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol. Oncol. 2014, 8:819-829.
69. Li Y., Kowdley K.V. Method for microRNA isolation from clinical serum samples. Anal. Biochem. 2012, 431:69-75.
70. Pritchard C.C., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila.) 2012, 5:492-497.
71. Xiao F., et al. Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur. J. Cancer 2014, 50:1541-1554.
72. Liu M.X., et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5:944-958.
73. Janssen H.L.A., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
74. Gebert L.F.R., et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014, 42:609-621.
75. Bader A.G. miR-34 - a microRNA replacement therapy is headed to the clinic. Front. Genet. 2012, 3:120.
76. Kelnar K., et al. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal. Chem. 2014, 86:1534-1542.
77. Wiggins J.F., et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
78. Obad S., et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 2011, 43:371-378.
79. Sethupathy P., et al. TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA 2006, 12:192-197.